Bank of Baroda stock slips as NMC trial nears 2026

Market snapshot: shares in the red

Bank of Baroda shares were trading lower on Thursday, July 2, 2026. The stock was quoted at ₹267.75, down 1.38% versus the previous close of ₹271.50. During the session, it moved in a reported band of ₹274.65 to ₹267.40.

The stock’s near-term trend also remained weak in the data provided. Bank of Baroda was shown down 2.21% over the last five days and down 8.20% year-to-date. These moves frame investor sentiment at a time when the lender is facing both operating concerns around margins and a high-profile overseas legal dispute.

A second quote feed highlights wider intraday swings

The information set also included a separate trading snapshot showing a different set of intraday levels, with today’s high at ₹282.40, today’s low at ₹278.00, and previous close at ₹279.15. It also listed a 52-week high of ₹325.50 and a 52-week low of ₹230.81.

While these figures appear to come from a different market feed or time window than the ₹267.75 quote, together they highlight that Bank of Baroda has seen notable price movement within its 52-week range.

The NMC Health case: what the litigation is about

Bank of Baroda is one of three defendants in an ongoing fraud case linked to NMC Health, the UAE-based private healthcare provider that collapsed in 2020. The litigation has been brought by NMC’s administrator Alvarez & Marsal (A&M). The overall value of the claims has been estimated at at least US$1 billion, and elsewhere described as a US$1.4 billion case.

The dispute spans multiple jurisdictions and centres on events leading up to NMC’s collapse, which was associated with around US$1 billion in liabilities. Bank of Baroda, described as majority owned by the Indian government and as India’s second-largest public sector bank in the provided text, is alleged to have acted fraudulently and negligently, including alleged breaches of contractual and tortious obligations.

Trial schedule and what it implies for the bank

A 16-week trial is scheduled to begin on Monday, March 23, 2026 in the Abu Dhabi Global Market (ADGM) courts. A separate reference in the provided information also described the trial’s scheduled period as May and June 2026, indicating that key hearings may extend across those months.

Counsel involved in the matter characterised it as a “great reputational matter”, signalling that the stakes go beyond any direct financial award. The same material also noted practical implications, including significant legal costs and management bandwidth being diverted while the case proceeds.

Claims, counter-claims, and a separate dismissal in the US

The administrators allege fraud on a massive scale by the other two defendants, B.R. Shetty and Prasanth Manghat, who served as CEO of NMC Health from 2017 until its 2020 collapse. Bank of Baroda’s position is complicated by the fact that it is also pursuing its own recovery actions. In separate proceedings, the bank is suing Shetty and NMC Health to recover around US$150 million.

Separately, an US$1 billion lawsuit filed by NMC founder B.R. Shetty against Bank of Baroda was dismissed in New York in July 2024 on procedural grounds. The material noted Shetty’s intent to pursue claims in Abu Dhabi, suggesting continued legal pressure even after the New York dismissal.

Financial and valuation context investors are watching

As of February 23, 2026, Bank of Baroda’s stock traded around ₹313.30, and its market capitalisation was cited at approximately ₹1.60 trillion, which equals about ₹160,000 crore. The lender was also described as trading at a P/E ratio of roughly 8.21 to 8.35 and a P/B ratio of approximately 0.97.

The same information set referenced a generally positive analyst stance, with a consensus rating of “Buy” or “Moderate Buy” and an average 12-month target indicating about 7% to 8% upside from then-current levels, while cautioning that targets may not fully incorporate the litigation’s potential financial impact and any subsequent regulatory actions.

Q3 FY26: profit up, but NII misses trigger downgrades

Operationally, recent quarterly performance has been a key driver of near-term stock moves. In Q3 FY26, Bank of Baroda’s net profit rose 4.5% year-on-year to ₹5,055 crore, helped by lower provisioning and a marginal rise in non-interest income. However, net interest income (NII) was flat at ₹11,800 crore, compared with ₹11,786 crore a year earlier.

After the Q3 print, the stock extended losses on a Monday session following multiple downgrades linked to a miss on NII estimates. The stock fell as much as 2.7% intraday to ₹272 per share, a day after a 7% decline. It later traded about 2.2% lower at ₹273.4, while the Nifty 50 was slightly higher by 0.06% at the time cited. Bloomberg data in the text also indicated trading volume at 2.7 times the average 30-day volume.

Q4 FY25: NII declines as margins tighten

In Q4 FY25 (quarter ended March 2025), Bank of Baroda reported a 3.3% year-on-year rise in standalone net profit to ₹5,048 crore, versus ₹4,886 crore a year earlier. But NII fell 6.6% to ₹11,020 crore, from ₹11,793 crore, reflecting pressure on net interest margins.

The lender earned ₹30,642 crore in interest income in the quarter, up from ₹29,583.40 crore, while interest expenses rose to ₹19,622.39 crore from ₹17,790.57 crore. A Reuters report cited domestic net interest margin slipping to 3.02% from 3.45%, and CEO Debadatta Chand saying the bank expects margin challenges to persist through the first two quarters of the fiscal year that began April 1.

Key facts table: price, legal, and financial metrics

Why this matters for investors: two distinct risk tracks

Bank of Baroda’s recent trading action reflects two parallel concerns shown in the material. First, the core banking story: margins and NII have been under pressure, and management has flagged that margin challenges may persist through the early quarters of the fiscal year. Second, the overseas litigation track: the NMC Health case is described as reputationally significant and financially meaningful, with legal spend and management time commitment explicitly noted.

There is also a compliance-related layer. The data provided stated that the lender has successfully invoked confidential information related to money laundering submitted to the UAE Central Bank, in the context of accusations tied to alleged fraud involving Shetty and Manghat. That connection keeps the dispute in focus for investors tracking potential regulatory scrutiny and operational implications.

Conclusion: what to watch next

Bank of Baroda shares have been volatile in the information provided, with declines linked to margin pressure and NII-related downgrades, alongside a large, multi-jurisdiction legal dispute tied to NMC Health. The next clear marker is the ADGM trial schedule beginning March 23, 2026, with proceedings referenced across May and June 2026 as well. Investors will also watch for further updates on margins, NII trends, and any disclosures related to the Abu Dhabi litigation and recovery actions of around US$150 million.